Probiotics and the Colon

Therapeutic and Prophylactic Uses
  • Thomas J. Borody
  • Patricia L. Conway


In the past, probiotic use has been shrouded by scepticism because of a lack of scientifically valid evidence of efficacy and with the science behind the concept lost to the culinary world of yogurt production. A new generation of probiotics is emerging in the new millennium as the potential savior of colonic disturbances that plague up to 30% of the general public. It is now recognized that with stringent probiotic strain selection criteria and demonstration of measurable parameters of functionality, probiotics can effectively prevent, reduce, or even eliminate many colonic disorders. Some of the targeted disorders have only recently been linked to the indigenous bowel flora, and as yet, no specific pathogens have been identified. Probiotics can be used either directly or indirectly to affect these putative causal agents, even if they have not yet been unmasked, and to restore the balance of beneficial microbes, thereby improving symptoms. While these new probiotic preparations can be included in foods, clinical evidence of efficacy will lead to the development of effective pharmaceutical probiotic products for colonic applications.


Ulcerative Colitis Irritable Bowel Syndrome Lactic Acid Bacterium Irritable Bowel Syndrome Patient Probiotic Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shaw HW. The Complete Works of Josh Billings. ( With one hundred illustrations by Thomas Nast and others, and a biographical introduction.) Dillingham, New York, NY, 1876.Google Scholar
  2. 2.
    Fuller R. History and development of probiotics. In Probiotics: The Scientific Basis. Fuller R (ed.), Chapman und Hall, London, UK, 1992, pp. 1–4.Google Scholar
  3. 3.
    Salminen S, Bouley C, Boutron-Ruault M-C, et al. Functional food science and gastrointestinal physiology and function. Brit. J. Nutr., 80 (1998) 147–171.CrossRefGoogle Scholar
  4. 4.
    Parker RB. Probiotics, the other half of the antibiotic story. Anim. Nutr. Health, 29 (1974) 4–8.Google Scholar
  5. 5.
    Metchnikoff E. The Prolongation of Life, ist ed., Putnam Sons, New York, NY, 1908.Google Scholar
  6. 6.
    Rettger LF, Chaplin HA. Treatise on the Transformation of the Intestinal Flora with Special Reference to the Implantation of Bacillus acidophilus. Yale University Press, New Haven, CT, 1921.Google Scholar
  7. 7.
    Conway PL. Lactobacilli: fact and fiction. In The Regulatory and Protective Role of the Normal Microflora. Grubb R, Midtvedt T, Norin E (eds.), The MacMillan Press LDT, London, UK, 1989, pp. 263–282.Google Scholar
  8. 8.
    Altas R. Probiotics-snake oil for the new millennium. Environ. Microbiol., 1 (1999) 377–382.CrossRefGoogle Scholar
  9. 9.
    Berg RD. Probiotics, prebiotics or conbiotics. Trends Microbiol., 6 (1998) 89–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Mattila-Sandholm T. The PROBDEMO project: demonstration of the nutritional functionality of probiotic foods. Tr. Food Sci. Tech.,10 (1999;) 385–386.Google Scholar
  11. 11.
    Havenaar H, Ten Brink B, Huis In’t Veld J. Selection of strains for probiotic use. In Probiotics: The Scientific Basis. Fuller R (ed.), Chapman und Hall, London, UK, 1992, pp. 209–224.Google Scholar
  12. 12.
    Conway PL, Henriksson A. Strategies for the isolation and characterisation of functional probiotics. In Human Health: The Contribution of Microorganisms. Gibson S (ed.), Springer-Verlag, London, UK, 1994, pp. 119–144.Google Scholar
  13. 13.
    Conway PL. Selection criteria for probiotic microorganisms. Asian Pac. J. Clin. Nutr., 5 (1996) 10–14.Google Scholar
  14. 14.
    Blum S, Reniero R, Schiffrin EJ, et al. Adhesion studies for probiotics: need for validation and refinement. Tr. Food Sci. Tech., 10 (1999) 405–410.CrossRefGoogle Scholar
  15. 15.
    Conway PL: Acquisition and Succession of the gut microflora. In The Gastrointestinal Microflora. Vol. 2, Mackie RI, White BA, Isaacson RE (eds.), International Thomson Publishing, New York, NY, 1996, pp. 3–38.Google Scholar
  16. 16.
    Salminen S. Human studies on probiotics. Aspects of scientific documentation. Scand. J. Nutr., 45 (2001) 8–12.Google Scholar
  17. 17.
    Pathmakanthan SA, Meance S, Edwards CA. Probiotics: A review of human studies to date and methodological approaches. Microb. Ecol. Health Dis., 12 (2000) S10 - S30.CrossRefGoogle Scholar
  18. 18.
    Sanders ME, Huis in’t Veld J. Bringing a probiotic-containing functional food to the market: microbiological, product regulatory and labelling issues. Antonie van Leeuwenhoek, 76 (1999) 293–315.Google Scholar
  19. 19.
    Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA, 275 (1996) 870–876.PubMedCrossRefGoogle Scholar
  20. 20.
    McFarland LV. A review of the evidence of health claims for biotherapeutic agents. Microb. Ecol. Health Dis., 12 (2000) 65–76.CrossRefGoogle Scholar
  21. 21.
    Lodinova-Zadnikoa R, Sonnenborn U, Tlaskalova H. Probiotics and E. coli infections in man. Vet. Q., 20 (1998) S78 - S91.Google Scholar
  22. 22.
    Okamoto T, Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T, Kusunoki M. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J. Gastroenterol., 35 (2000) 341–346.PubMedCrossRefGoogle Scholar
  23. 23.
    Kuroika T, Iwanaga M, Kobari K, Higashionna A, Kinjyo F, Saito A. Preventive effect of Clostridium butyricum M588 against the proliferation of Clostridium difficile during antimicrobial therapy. J. Jpn. Assoc. Infect. Dis., (1990) 1425–1432.Google Scholar
  24. 24.
    Pascual M, Hugas M, Badiola JI, Monfort JM, Garriga M. Lactobacillus salivarius CTC2197 prevents Salmonella enteritidis colonisation in chickens. Appl. Environ. Microbiol., 65 (1999) 4981–4986.PubMedGoogle Scholar
  25. 25.
    Conway PL. Probiotics and the gastrointestinal microbiota. In Germfree Life and Its Ramifications. Hashimoto K, Sakakibara B, Tazume S, Shimizu K (eds.), XII ISG Publishing Committee, Shiozawa, Japan, 1997, pp. 97–100.Google Scholar
  26. 26.
    Jacobsen CN, Rosenfeldt-Nielsen V, Hayford AE, et al. Screening of probiotics activities of forty-seven strains of Lacatobacillus spp by in vitro techniques and evaluation of the colonisation ability of five selected strains in humans. Appl. Environ. Microbiol., 65 (1999) 4949–4956.PubMedGoogle Scholar
  27. 27.
    Dunne C, Murphy L, Flynn S, et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie von Leeuwenhoek, 76 (1999) 279–292.CrossRefGoogle Scholar
  28. 28.
    Barrow PA, Fuller R, Newport MJ. Changes in the microflora and physiology of the anterior intestinal tract of pigs weaned at 2 d, with special reference to the pathogenesis of diarrhea. Infect. Immun., 18 (1977) 586–595.PubMedGoogle Scholar
  29. 29.
    Blomberg L, Conway PL. An in vitro study of colonisation resistance to Escherichia coli strain Bd 1107/7508 (K88) in relation to indigenous squamous gastric colonisation in piglets of varying ages. Microb. Ecol. Health Dis., 2 (1989) 285–291.CrossRefGoogle Scholar
  30. 30.
    Fuller R. Probiotics in man and animals. J. Appl. Bacteriol., 66 (1989) 365–378.PubMedCrossRefGoogle Scholar
  31. 31.
    van der Waaij D, Berguis-de Vries JM, Lekkerkerk-v. Colonisation resistance of the digestive tract in conventional and antibiotic-treated mice. J. Hyg., 69 (1971) 405–411.CrossRefGoogle Scholar
  32. 32.
    Blomberg L, Henriksson A, Conway PL. Inhibition of Escherichia coli K88 to piglet ileal mucus by Lactobacillus spp. Appl. Environ. Microbiol., 59 (1993) 34–39.PubMedGoogle Scholar
  33. 33.
    Fox SM. Probiotics: intestinal inoculants for production animals. Vet. Med., 83 (1988) 806–830.Google Scholar
  34. 34.
    Lindgren SE, Dobrogosz WJ. Antagonistic activities of lactic acid bacteria in food and feed fermentations. FEMS Microbiol. Rev., 87 (1990) 149–164.CrossRefGoogle Scholar
  35. 35.
    Cunningham-Rundles S, Ahrne S, Bengmark S, et al. Probiotics and immune response. Am. J. Gastoenterol., 95 (2000) 522–825.Google Scholar
  36. 36.
    Wallace RJ, Newbold CJ. Microbial feed additives for ruminants. In Old Herborn University Seminar Monographs. Fuller R, Heidt PJ, Rusch V, Van der Waaij D (eds.), Institute for Microbiology und Biochemistry, Herborn, Germany, 1995, pp. 101–125.Google Scholar
  37. 37.
    Mattila-Sandholm T, Blum S, Collins JK, et al. Probiotics: towards demonstrating efficacy. Tr. Food Sci. Tech., 10 (1999) 393–399.CrossRefGoogle Scholar
  38. 38.
    Bottcher MF, Nordin EK, Sandin A, Midtvedt T, Bjorksten B. Microflora-associated characteristics in faeces from allergic and nonallergic infants. Clin. Exp. Allergy, 30 (2000) 1590–1596.PubMedCrossRefGoogle Scholar
  39. 39.
    Vaughan EE, Heilig HGHJ, Zoetendal EG, et al. Molecular approaches to study probiotic bacteria. Tr. Food Sci. Tech., 10 (1999) 400–404.CrossRefGoogle Scholar
  40. 40.
    Saxelin M, Grenov B, Svenson U, Fondèn R, Reniero R, Sandholm-Mattila T. The technology of probiotics. Tr. Food Sci. Tech., 10 (1999) 387–392.CrossRefGoogle Scholar
  41. 41.
    Elli M, Zink R, Reniero R, Morelli L. Growth requirements of Lactobacillus johnsonii in skim and UHT milk. Int. Dairy J., 9 (1999) 507–513.CrossRefGoogle Scholar
  42. 42.
    Aguirre M, Collins MD. Lactic acid bacteria and human clinical infection. J. Appl. Bacteriol., 75 (1993) 95–107.PubMedCrossRefGoogle Scholar
  43. 43.
    Gasser F. Safety of lactic acid bacteria and their occurrence in human clinical infections. Bull. Inst. Pasteur, 92 (1994) 45–67.Google Scholar
  44. 44.
    O’Brien JO, Crittenden R, Ouwehand A, Salminen S. Safety evaluation of probiotics. Tr. Food Sci. Tech., 10 (1999) 418–424.CrossRefGoogle Scholar
  45. 45.
    Marteau P. Safety aspects of probiotic products. Scand. J. Nutr., 45 (2001) 22–24.Google Scholar
  46. 46.
    Adams MR. Safety of industrial lactic acid bacteria. J. Biotechnol., 68 (1999) 171–178.PubMedCrossRefGoogle Scholar
  47. 47.
    Harty DWS, Oakey JH, Patrikakis M, Hume EBH, Knox KW. Pathogenic potential of lactobacilli. Int. J. Food Microbiol., 24 (1994) 179–189.PubMedCrossRefGoogle Scholar
  48. 48.
    Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in Southern Finland 1989–1999. Clin. Infect. Dis., 22 (1996) 564–566.PubMedCrossRefGoogle Scholar
  49. 49.
    Saxelin M, Rautelin H, Salminen S, Makela P. The safety of commercial products with viable Lactobacillus strains. Infect. Dis. Clin. Pract., 5 (1996) 331–335.CrossRefGoogle Scholar
  50. 50.
    MacKay AD, Tylor MB, Kibbler CC, Hamilton-Miller JMT. Lactobacillus endocarditis caused by a probiotic organism. Clin. Microbiol. Infect., 5 (1999) 290–292.PubMedCrossRefGoogle Scholar
  51. 51.
    Rautio M, Jousimies H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus indistinguishable from L. rhamnosus GG. Clin. Infect. Dis., 28 (1999) 1159–1160.PubMedCrossRefGoogle Scholar
  52. 52.
    Pletinex M, Legein J, Vanenplas Y. Fungicemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J. Pediatr. Gastroenterol. Nutr., 21 (1995) 113–115.CrossRefGoogle Scholar
  53. 53.
    Niault M, Thomas F, Prost J, Ansari FH, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin. Infect. Dis., 28 (1999) 930.PubMedCrossRefGoogle Scholar
  54. 54.
    Perapoch J, Planes AM, Querol A, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with Ultra-Levura. Eur. J. Clin. Microbiol. Infect. Dis., 19 (2000) 468–470.PubMedCrossRefGoogle Scholar
  55. 55.
    Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur. J. Clin. Microbiol. Infect. Dis., 19 (2000) 16–20.PubMedCrossRefGoogle Scholar
  56. 56.
    Mitsuoka T. Intestinal Bacteria and Health. Harcourt Brace Jovanovich, Tokyo, 1978.Google Scholar
  57. 57.
    Tannock GW. Analysis of the intestinal microflora: a renaissance. Antonie von Leeuwenhoek, 76 (1999) 265–278.CrossRefGoogle Scholar
  58. 58.
    Shorn C. The probiotic century: historical and current perspectives. Tr. Food Sci. Tech., 10 (1999) 411–417.CrossRefGoogle Scholar
  59. 59.
    Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhea and in the treatment of acute diarrhea. J. Int. Med. Res., 17 (1989) 333–338.PubMedGoogle Scholar
  60. 60.
    Bellomo G, Mangiagle A, Nicastro L, Frigerio G. A controlled double-blind study of SF68 strain as a new biological preparation for the treatment of diarrhea in pediatrics. Curr. Ther. Res., 28 (1980) 927–936.Google Scholar
  61. 61.
    Mitra AK, Rabbani GB. A double-blind, controlled trial of Bioflorin (Streptococcus faecium SF68) in adults with acute diarrhea due to Vibrio cholerae and enterotoxigenic Escherichia coli. Gastroenterology, 99 (1990) 1149–1152.Google Scholar
  62. 62.
    Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp GG) promotes recovery from acute diarrhea in children. Pediatrics, 88 (1991) 90–97.PubMedGoogle Scholar
  63. 63.
    Isolauri E, Aila M, Mykkanen H, Ling WH, Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig. Dis. Sci., 39 (1994) 2595–2600.PubMedCrossRefGoogle Scholar
  64. 64.
    Shornikova AV, Casas IA, Mykkanen H, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr. Infect. Dis. J., 16 (1997) 1103–1107.PubMedCrossRefGoogle Scholar
  65. 65.
    Saint-Marc T, Blehaut H, Touraine JL. AIDS-related diarrhea: a double blind trial of Saccharomyces boulardii. Sem. Hop., 71 (1995) 735–741.Google Scholar
  66. 66.
    Chapoy P. Traitement des diarrhees aigues infantiles: essai contrôlé de Saccharomyces boulardii. Ann. Pediatr., 32 (1985) 561–563.Google Scholar
  67. 67.
    Surawiscz CM, McFarland LV, Elmer GW, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am. J. Gastroenterol., 84 (1989) 1285–1287.Google Scholar
  68. 68.
    Mcfarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. DAMA,271 (1994) 19131918.Google Scholar
  69. 69.
    Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet, 2 (1987) 1519.Google Scholar
  70. 70.
    Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J. Pediatr. Gastroenterol. Nutr., 21 (1995) 224–226.PubMedCrossRefGoogle Scholar
  71. 71.
    Andrews PJ, Barnes P, Borody TJ. Chronic constipation reversed by restoration of bowel flora. A case and a hypothesis. Eur. J. Gastroenterol. Hepatol., 4 (1992) 245–247.Google Scholar
  72. 72.
    Celik AF, Tomlin J, Read NW. The effect of oral vancomycin on chronic idiopathic constipation. Aliment. Pharmacol. Ther., 9 (1995) 63–68.Google Scholar
  73. 73.
    Mollenbrink M, Bruckschen E. Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor). Med. Klin., 89 (1994) 587–593.Google Scholar
  74. 74.
    Grimaud JC, Bouvier JG, Bertolini JG, Salducci J, Chiarelli P, Bouley C. Effects du lait fermenté contentant du Bifidobacterium sur le temps de transit colique. Gastroenterol. Clin. Biol., 17 (1993) Al27.Google Scholar
  75. 75.
    Mance S, Turchet P, Raimondi A, Antoine JM. Cayuéla C, Postaire E, Lucas C. Effects of a milk fermented by Bifidobacterium SP. Dn_173010 (BIOTM) on the oro-fecal transit time in elderly. Gut, 45 (1999) A327.CrossRefGoogle Scholar
  76. 76.
    Bartram HP, Scheppach W, Gerlach S, Ruckdeschel G, Kelber E, Kasper H. Does yoghurt enriched with Bifidobacrterium longum affect colonic microbiology and fecal metabolites in healthy subjects? Am. J. Clin. Nutr., 59 (1994) 428–432.PubMedGoogle Scholar
  77. 77.
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology, 119 (2000) 305–309.PubMedCrossRefGoogle Scholar
  78. 78.
    Friedman G, George J. Treatment of refractory pouchitis with prebiotic and probiotic therapy. Gastroenterology, 118 (2000) A778.CrossRefGoogle Scholar
  79. 79.
    Husebye E, Hellstrom PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig. Dis. Sci., 39 (1994) 946–956.PubMedCrossRefGoogle Scholar
  80. 80.
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol., 95 (2000) 3503–3506.PubMedCrossRefGoogle Scholar
  81. 81.
    Da-Rong Z, Xiao-Xv D, Takahashi M, Bao Y. Intestinal microflora changes in patients with irritable bowel syndrome after ingestion of Clostridium butyricum preparation. Chin. J. Gastroenterol., 3 (1998).Google Scholar
  82. 82.
    Nobaek S, Johansson M-L, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol., 95 (2000) 1222–1238.CrossRefGoogle Scholar
  83. 83.
    O’Sullivan MA, O’Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Digest. Liver Dis., 32 (2000) 294–301.CrossRefGoogle Scholar
  84. 84.
    Blaser MJ. Microbial causation of the chronic idiopathic inflammatory bowel diseases. Inflamm. Bowel Dis., 3 (1997) 225–229.CrossRefGoogle Scholar
  85. 85.
    Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut, 48 (2001) 132–135.PubMedCrossRefGoogle Scholar
  86. 86.
    Isolauri E. Probiotics and gut inflammation. Curr. Opin. Gastroenterol., 15 (1999) 534–537.PubMedCrossRefGoogle Scholar
  87. 87.
    Kruis W, Schutz E, Fric P. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 11 (1997) 853–859.PubMedCrossRefGoogle Scholar
  88. 88.
    Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet, 354 (1999) 635–639.PubMedCrossRefGoogle Scholar
  89. 89.
    Venturi A, Gionchetti F, Rizello F, et al. Impact on the composition of the fecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther., 13 (1999) 1103–1108.PubMedCrossRefGoogle Scholar
  90. 90.
    Rizzello F, Gionchetti P, Venturi A, et al. Prophylaxis of postoperative recurrence of Crohns disease combination of antibiotic and probiotic versus mesalazine. Digest. Liver Dis., 32 (2000) A69.CrossRefGoogle Scholar
  91. 91.
    Guslandi M, Mezzi G, Massimo S, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohns disease. Dig. Dis. Sci., 45 (2000) 1462–1464.PubMedCrossRefGoogle Scholar
  92. 92.
    Schulz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am. J. Gastroenterol., 95 (2000) S19 - S21.Google Scholar
  93. 93.
    Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by donated stool directly through a colonoscope. Am. J. Gastroenterol., 95 (200) 3283–3285.Google Scholar
  94. 94.
    Bowden TA, Mansberger AR, Lykins LE. Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis. Am. Surg., 47 (1981) 178–183.PubMedGoogle Scholar
  95. 95.
    Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 44 (1958) 854–859.PubMedGoogle Scholar
  96. 96.
    Schwan A, Sjolin S, Trottestam U. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet, 2 (1983) 845.PubMedCrossRefGoogle Scholar
  97. 97.
    Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet, 1 (1989) 1156–1160.PubMedCrossRefGoogle Scholar
  98. 98.
    Flotterod O, Hopen G. Refractory Clostridium difficile infection. Untraditional treatment of antibiotic-induced colitis. Tidsskr. Nor. Laegeforen., 111 (1991) 1364–1365.PubMedGoogle Scholar
  99. 99.
    Paterson DL, Irdell J, Whitby M. Putting back the bugs: bacterial treatment relieves chronic diarrhea. Med. J. Aust., 160 (1994) 232–233.PubMedGoogle Scholar
  100. 100.
    Lund-Tonnesen S, Berstad A, Schreiner A, Midtvedt T. Clostridium diffici/e-associated diarrhea treated with homologous feces. Tidsskr. Nor. Laegeforen., 118 (1998) 1027–1030.PubMedGoogle Scholar
  101. 101.
    Gustafsson A, Lund-Tonnesen S, Berstad A, Midtvedt T, Norin E. Fecal short-chain fatty acids in patients with antibiotic-associated diarrhea before and after fecal enema treatment. Scand. J. Gastroenterol.,33 (1998)721–727.Google Scholar
  102. 102.
    Gorbach SL. Lactic acid bacteria and human health. Ann. Med., 22 (1990) 37–41.PubMedCrossRefGoogle Scholar
  103. 103.
    Mahida YR, Rose F, Chan WC. Antimicrobial peptides in the gastrointestinal tract. Gut, 40 (1997) 161–163.PubMedGoogle Scholar
  104. 104.
    Gustaffson A, Berstad A, Lund-Tonnesen S, Midtvedt T, Norin E. The effect of fecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhea. Scand. J. Gastroenterol., 34 (1999) 580–586.CrossRefGoogle Scholar
  105. 105.
    Butt HL, Dunstan RH, McGregor NR, Roberts TK, Zerbes M, Klineberg U. Alteration of the bacterial microbial flora in chronic fatigue/pain patients. In Proceedings of the Clinical and Scientific Basis of Chronic Fatigue Syndrome: From Myth Towards Management. Sydney, Australia, Feb 1998.Google Scholar
  106. 106.
    Hart CA. Antibiotic resistance: an increasing problem? BMJ, 316 (1998) 1255–1256.PubMedCrossRefGoogle Scholar
  107. 107.
    Borody Ti, Noonan S, Cole P, et al. Oral vancomycin can reverse idiopathic constipation. Gastroenterology, 96 (1989) A52.Google Scholar
  108. 108.
    Andrews PJ, Borody Ti. Putting back the bugs: bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med. J. Aust., 159 (1993) 633–634.PubMedGoogle Scholar
  109. 109.
    Borody Ti, George L, Andrews PJ, et al. Bowel flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med. J. Aust., 150 (1989) 604.Google Scholar
  110. 110.
    Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet, 1 (1989) 164.PubMedCrossRefGoogle Scholar
  111. 111.
    Borody TJ. “Flora Power”. Fecal bacteria cure chronic C. difficile diarrhea. Am. J. Gastroenterol., 95 (2000) 3028–3029.PubMedGoogle Scholar
  112. 112.
    Pedone C, Bernabeu A, Postaire E, Bouley A, Reinert P. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114) on acute diarrhea in children attending day care centres. Int. J. Clin. Pract., 53 (1999) 179–184.PubMedGoogle Scholar
  113. 113.
    Saavadra JM, Baumann NA, Oung I, Pernan JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet, 344 (1994) 1046–1049.CrossRefGoogle Scholar
  114. 114.
    Guandalini S, Pensabene L, Zibri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicentre European trial. J. Pediatr. Gastroenterol., 30 (2000) 54–60.CrossRefGoogle Scholar
  115. 115.
    Oberhelman R, Gilman RH, Sheen P, et al. A placebo controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J. Paediatr., 134 (1999) 15–20.CrossRefGoogle Scholar
  116. 116.
    Ribeiro H, VanderhoofJA. Reduction of diarrheal illness following administration of Lactobacillus plantarum 299v in a daycare facility. J. Pediatr. Gastroenterol. Nutr., 26 (1998) 561.Google Scholar
  117. 117.
    McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med., 320 (1989) 204–210.PubMedCrossRefGoogle Scholar
  118. 118.
    Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a Lactobacillus preparation. Am. J. Hosp. Pharm., 36 (1979) 754–757.PubMedGoogle Scholar
  119. 119.
    Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP, 24 (1990) 382.PubMedGoogle Scholar
  120. 120.
    Orrhage, Brismar B, Nord CE. Effects of supplements of Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin. Microb. Ecol. Health Dis., 7 (1994) 17–25.CrossRefGoogle Scholar
  121. 121.
    Colombel JF, Cortot A, Neut C, Romond C. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects. Lancet, 2 (1987) 43.PubMedCrossRefGoogle Scholar
  122. 122.
    Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhea. Ann. Med., 22 (1990) 57–59.PubMedCrossRefGoogle Scholar
  123. 123.
    McFarland LV, Surawicz CM, Greenburg RN, et al. Prevention of beta lactam associated diarrhea by Saccharomyces boulardii compared to placebo. Am. J. Gastroenterol., 90 (1995) 439–448.PubMedGoogle Scholar
  124. 124.
    Freeman LD, Hooper DR, Lathen DF, Nelson, Harrison WO, Anderson DS. Brief prophylaxis with doxycyline for the prevention of traveler’s diarrhea. Gastroenterology, 4 (1983) 276–280.Google Scholar
  125. 125.
    Wistrom J, Norrby SR, Burman LG, Lundholm R, Jellheden B, Englund G. Norfloxacin versus placebo for prophylaxis against traveler’s diarrhea. J. Antimicrob. Chemother., 20 (1987) 563–574.PubMedCrossRefGoogle Scholar
  126. 126.
    Dupont HL, Sulivan P, Evans DG, et al. Prevention of traveller’s diarrhea (emporiatric enteritis): prophylactic administration of subsalicylate bismuth. JAMA, 243 (1980) 237–241.PubMedCrossRefGoogle Scholar
  127. 127.
    Black FT, Andersen PL, Orskov J, Orskov F, Gaarslev K, Laulund S. Prophylactic efficacy of lactobacilli on traveler’s diarrhea. In Travel Medicine. Conference on International Travel Medicine 1. Steffen R (ed.), Springer, Zurich, 1989, pp. 333–335.Google Scholar
  128. 128.
    Pozo-Olano JD, Warram JH, Gomez RG, Cavazos MG. Effect of a Lactobacilli preparation preparation on traveler’s diarrhea. Gastroenterology, 74 (1978) 829–830.Google Scholar
  129. 129.
    Orksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers diarrhea by Lactobacillus GG. Ann. Med., 22 (1990) 53–56.CrossRefGoogle Scholar
  130. 130.
    Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prophylaxe der Reisediarrhee mit Saccharomyces boulardii. Fortschr. Med., 111 (1993) 153–156.Google Scholar
  131. 131.
    Katelaris PH. Probiotic control of diarrheal disease. Asian Pac. J. Clin. Nutr., 5 (1995) 39–43.Google Scholar
  132. 132.
    Hirayama K, Rafter J. The role of lactic acid bacteria in colon cancer prevention: mechanistic considerations. Antonie van Leeuwenhoek, 76 (1999) 391–394.PubMedGoogle Scholar
  133. 133.
    Parodi PW. The role of intestinal bacteria in the causation and prevention of cancer: modulation by diet and probiotics. Am. J. Dairy Technol., 54 (1999) 103–121.Google Scholar
  134. 134.
    Wollowski I, RechkemmerG, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am. J. Clin. Nutr., 73 (2001) S451 - S455.Google Scholar
  135. 135.
    McIntosh GH, Royle PJ, Playne MJ. A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. Nutr. Cancer, 35 (1999) 153–159.PubMedCrossRefGoogle Scholar
  136. 136.
    Gorbach S. Probiotics and gastrointestinal health. Am. J. Gastroenterol., 95 (2000) S2 - S4.PubMedCrossRefGoogle Scholar
  137. 137.
    Goldin B. The metabolic activity of the intestinal microflora and its role in colon cancer. Nutr. Today, 31 (1996) S24 - S27.CrossRefGoogle Scholar
  138. 138.
    Yamazaki K, Tsunoda A, Sibusawa M, et al. The effect of an oral administration of Lactobacillus casei strain Shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. Oncol. Rep., 7 (2000) 977–982.PubMedGoogle Scholar
  139. 139.
    Reddy BS. Possible mechanisms by which pro-and prebiotics influence carcinogenesis and tumor growth. J. Nutr., 129 (1999) 51478–51482.Google Scholar
  140. 140.
    Orrhage K, Sillerstrom E, Gustafsson JA, Nord CE, Rafter J. Binding of mutagenic heterocyclic amines by intestinal lacttic acid bacteria. Mutat. Res., 311 (1994) 239–248.PubMedCrossRefGoogle Scholar
  141. 141.
    Orrhage K. Impact of Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microflora and bioavailability of some food mutagens. PhD Thesis, Karolinska Institute, Stockholm, Sweden 1999.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2003

Authors and Affiliations

  • Thomas J. Borody
  • Patricia L. Conway

There are no affiliations available

Personalised recommendations